Tachihara Motoko, Yamamoto Masatsugu, Yumura Masako, Yoshizaki Asuka, Kobayashi Kazuyuki, Nishimura Yoshihiro
Division of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.
Respirol Case Rep. 2019 Jan 31;7(3):e00404. doi: 10.1002/rcr2.404. eCollection 2019 Apr.
We present the case of a 70-year-old man with stage IV lung adenocarcinoma. He was treated with pembrolizumab, a programmed cell death-1 (PD-1) inhibitor, as a first-line therapy. After six cycles of pembrolizumab, he suddenly developed cardiac tamponade. With the exception of newly massive malignant pericardial effusion, the other malignant lesions improved. Pembrolizumab was continued and the patient has shown a durable response for two years. This is the unique case of late-onset pericaridial effusion with pembrolizumab, showed discrepant anti-tumour effects. A proper assessment is crucial to ensure favourable clinical outcomes in patients treated with PD-1 inhibitor.
我们报告了一例70岁的IV期肺腺癌男性患者的病例。他接受了帕博利珠单抗（一种程序性细胞死亡蛋白1 [PD-1]抑制剂）作为一线治疗。在接受六个周期的帕博利珠单抗治疗后，他突然出现了心脏压塞。除了新出现的大量恶性心包积液外，其他恶性病变有所改善。继续使用帕博利珠单抗治疗，该患者已显示出两年的持久反应。这是帕博利珠单抗导致迟发性心包积液的独特病例，显示出抗肿瘤效果的差异。进行适当评估对于确保接受PD-1抑制剂治疗的患者获得良好临床结果至关重要。
